September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The predictive features of optical coherent topography in anatomical response to ranibizumab in patients with diabetic macular edema
Author Affiliations & Notes
  • Angela Ding
    Ophthalmology, Oxford Eye Hospital, Oxford, United Kingdom
  • Samia Fatum
    Ophthalmology, Oxford Eye Hospital, Oxford, United Kingdom
  • Victor Chong
    Ophthalmology, Oxford Eye Hospital, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships   Angela Ding, None; Samia Fatum, None; Victor Chong, Allergan (C), Bayer (C), Novartis (C), Pfenex (C), Quantel Medical (C)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2090. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Angela Ding, Samia Fatum, Victor Chong; The predictive features of optical coherent topography in anatomical response to ranibizumab in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2090.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Anti-vascular endothelial growth factor (VEGF) agents are now considered to be the first line therapy for patients with visual loss due to foveal involving diabetic macular edema (DME). However, in many patients, the response is sub-optimal, and about 25%, there is no anatomical response in the first 6 months. As we now have other options, such as steroids and surgery, it might be useful to predict those with poor anatomical response and consider steroids or surgery as first line therapy.

Methods : A total of 152 consecutive foveal involving DME patients, who have received ranibizumab 0.5 mg (an anti-VEGF agent) monthly for 6 months were included in the study. All patients had spectral-domain optical coherent topography (SD-OCT) using Heidelberg Spectralis (Heidelberg, Germany) at baseline and at 6 months (1 month after the last injection). We divided the patients into 3 groups based on the reduction of central sub-field thickness (CST), namely non-responder NR (<10% reduction), partial-responder PR (>10% reduction but not normal), and good responder GR (normal central thickness). The baseline SD-OCT were scored based on the presence or absence of the following features, subretinal fluid, petalloid appearances, foveal eversion, foval edema, epiretinal membrane (ERM) and central foveal cyst. Only the NR and the GR groups were used for statistical analysis using Chi-Square test.

Results : There were 47 (31%) patients in the NR group (average age 68, 52% female), 35 (23%) in the PR group (average age 67, 30% female), and 70 (46%) in the GR group (average age 67, 40% female). There were no statistical significant difference in all the analysed features except the presence of ERM (51.1% in NR vs 27.1% in GR group, p=0.008). The presence of subretinal fluid was less common in the NR group but did not reach statistical significant (10.6% in NR vs 20.0 % in GR group, p=0.10).

Conclusions : The presence of ERM statistically increases the risk of non-anatomical responding in SD-OCT with 6 ranibizimab injections in DME patients. It is unclear whether the thickness or the location of the ERM would increase the prediction value. Furthermore, it is unclear whether steroids would be useful in this group of patients. Surgical intervention might be needed in some cases.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.